Stina Axelsson

Summary

Country: Sweden

Publications

  1. ncbi Decreased GAD(65)-specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum
    S Axelsson
    Division of Paediatrics, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    Diabet Med 29:1272-8. 2012
  2. ncbi Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65)
    Stina Axelsson
    Division of Paediatrics and Diabetes Research Centre, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    Diabetes Metab Res Rev 26:559-68. 2010
  3. ncbi Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes
    Stina Axelsson
    Division of Paediatrics, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    PLoS ONE 6:e29008. 2011
  4. ncbi GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients
    Maria Hjorth
    Division of Pediatrics and Diabetes Research Center, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    Clin Immunol 138:117-26. 2011
  5. ncbi Cryopreserved peripheral blood mononuclear cells are suitable for the assessment of immunological markers in type 1 diabetic children
    Stina Axelsson
    Division of Paediatrics and Diabetes Research Centre, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, S 581 85 Linkoping, Sweden
    Cryobiology 57:201-8. 2008
  6. ncbi GAD treatment and insulin secretion in recent-onset type 1 diabetes
    Johnny Ludvigsson
    Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    N Engl J Med 359:1909-20. 2008
  7. ncbi Immune intervention in children with type 1 diabetes
    Johnny Ludvigsson
    Department of Clinical and Experimental Medicine, Division of Pediatrics, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    Curr Diab Rep 10:370-9. 2010

Detail Information

Publications7

  1. ncbi Decreased GAD(65)-specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum
    S Axelsson
    Division of Paediatrics, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    Diabet Med 29:1272-8. 2012
    ..We aimed to study the immunomodulatory effect of glutamic acid decarboxylase (GAD) 65 formulated with aluminium hydroxide (GAD-alum) in children with Type 1 diabetes, focusing on chemokines and their receptors...
  2. ncbi Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65)
    Stina Axelsson
    Division of Paediatrics and Diabetes Research Centre, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    Diabetes Metab Res Rev 26:559-68. 2010
    ....
  3. ncbi Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes
    Stina Axelsson
    Division of Paediatrics, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    PLoS ONE 6:e29008. 2011
    ..In parallel to a GAD(65)-induced T-cell activation, our results show induction of T-cell inhibitory pathways important for regulating the GAD(65) immunity...
  4. ncbi GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients
    Maria Hjorth
    Division of Pediatrics and Diabetes Research Center, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    Clin Immunol 138:117-26. 2011
    ..These new data suggest that GAD-alum treatment induced GAD(65)-specific T cells with regulatory features...
  5. ncbi Cryopreserved peripheral blood mononuclear cells are suitable for the assessment of immunological markers in type 1 diabetic children
    Stina Axelsson
    Division of Paediatrics and Diabetes Research Centre, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, S 581 85 Linkoping, Sweden
    Cryobiology 57:201-8. 2008
    ..Thus, cryopreserved PBMC were suitable to assess the immunological markers included in this study, even though their expression could differ from freshly handled cells...
  6. ncbi GAD treatment and insulin secretion in recent-onset type 1 diabetes
    Johnny Ludvigsson
    Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    N Engl J Med 359:1909-20. 2008
    ..This trial assessed the ability of alum-formulated GAD (GAD-alum) to reverse recent-onset type 1 diabetes in patients 10 to 18 years of age...
  7. ncbi Immune intervention in children with type 1 diabetes
    Johnny Ludvigsson
    Department of Clinical and Experimental Medicine, Division of Pediatrics, Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    Curr Diab Rep 10:370-9. 2010
    ..Combination of immune intervention, protection of the beta cells, and stimulation of regeneration may lead to a milder disease or even a cure in the future, and prevention is no longer unrealistic...